Summary A total of 169 colorectal adenocarcinomas, obtained from patients with a median follow-up of 6.5 years, were studied with immunohistochemical staining on cryosections using a monoclonal anti-tenascin antibody to evaluate the possible association between the staining patterns and tumour stage, tumour differentiation and survival. We found two different staining patterns in the tumour stroma -a diffuse stromal fibrillar staining in 92 out of 169 (54%) tumours and a subglandular staining in the remaining 77 tumours. When the entire group of patients (P < 0.01) and the group of potentially cured patients (P < 0.03) were analysed univariately, it was found that diffuse stromal fibrillar staining was associated with a shorter survival time than subglandular staining. In a multivariate analysis, the Dukes' stage and age were independent prognostic factors, whereas the tenascin expression did not retain a clear independent relationship to survival (P = 0.06).
Tenascin is a large hexameric extracellular matrix protein that is present during embryonic development but essentially absent in normal adult tissues (Schenk and Chiquet-Ehrismann, 1994) and is expressed only at low levels or in a very restricted distribution. Several tenascin isoforms have been described . Tenascin has been suggested to be of importance in the normal healing process and in tumours, in which its role is presumed to be connected with cell adhesion and detachment, cell growth, cell migration and angiogenesis (Mackie et al, 1988 ; Ekblom and Aufterheide, 1989; Erickson and Bourdon, 1989; ChiquetEhrismann, 1993; Hahn et al, 1995; Joshi et al, 1995) . It has been proposed that, although tenascin has no cell adhesion activity, it does affect the cell shape and, thus, may inhibit cell attachment to other extracellular proteins, including fibronectin (Mackie, 1994) . It is also thought that tenascin plays a role in coordinating the provisional extracellular matrix surrounding the cancer tissue (Sakakura and Kusakabe, 1994) .
Several reports have shown an up-regulation of tenascin in various tumour stroma, such as breast (Moch et al, 1993; Shoji et al, 1993; Yoshida et al, 1995) , lung (Natali and Zardi, 1989) , prostatic (Ibrahim et al, 1993) and gastric carcinomas (Ikeda et al, 1995; Ilunga and Iriyama, 1995) . Studies of this putative marker of the tumour matrix are also of considerable interest in colorectal cancer (Sugawara et al, 1991; Riedel et al, 1992; Sakai et al, 1993; Hauptmann et al, 1995; Riedel et al, 1995) because of the potential involvement of tenascin (or tenascin-like proteins) in cell adhesion and invasion during the metastatic process. Moreover, diagnostic and possibly therapeutic monoclonal antibodies, specific for the larger tenascin isoforms present in tumours, have been developed (Leprini et al, 1994) .
In order to search for prognostic markers in colorectal cancer, especially in Dukes' stages B and C, which are associated with a high relapse rate (and for which adjuvant therapy could be an option), we investigated the expression of tenascin in 169 tumours from a prospective series of patients resected for colorectal cancer. The staining patterns were evaluated in relation to common clinicopathological variables and patient survival time. classification. The tumours were graded according to the WHO classification (Morson and Sobin, 1976) and were staged according to the Dukes' classification system (Dukes and Bussey, 1958 Immunohistochemical detection Acetone-fixed 6-tm cryosections were stained with the mouse monoclonal antibody BC-4 to tenascin (kindly provided by Dr P Ekblom, Department of Zoophysiology, Biomedical Center, University of Uppsala, Sweden). The avidin-biotin method, containing a peroxidase conjugate, was used (ABC Elite, Vector, Burlingame, CA, USA). The primary antibody was used at a dilution of 1:125 in phosphate-buffered saline supplemented with 5% normal horse serum and 1% bovine serum albumin, and was incubated with tissues for 60 min at room temperature. The primary antibody was then omitted and was replaced by either dilution buffer or normal mouse IgG, as negative controls. The secondary antibody, biotinylated horse anti-mouse IgG from Vector Laboratories, was used at a dilution of 1:200 and was incubated for 30 min.
MATERIALS AND METHODS Patients

Immunohistopathological evaluation
Tenascin staining patterns were examined by light microscopy, at a magnification of x125. Coded slides from all 169 tumours were evaluated without prior knowledge of tumour stage or clinical outcome. In order to assess the interobserver agreement, two of the authors (UK, GL) evaluated 20 randomly selected and blinded sections.
Statistical methods
The Cox proportional hazards model was used (Lawless, 1992) in both the univariate and the multivariate survival analyses. Likelihood ratio and Wald tests were used in the testing. Survival curves were constructed using the Kaplan-Meier method, and differences between curves were tested using the log-rank test. The proportion of patients with diffuse tenascin expression among different categories of Dukes' stage and differentiation was analysed using the logistic regression model. Trend tests were also used for these ordinally scaled variables to increase the statistical power.
RESULTS
Tenascin staining patterns
Extensive fibrillar tenascin positivity was constantly seen in the tumour matrix, whereas tumour epithelial cells were entirely negative. Tenascin expression was generally seen in muscularis mucosae, in muscularis propia and in the vessel walls. Minimal staining, if any, was detectable in the adjacent normal bowel wall. There were two different tenascin stromal fibrillar staining patterns -a subglandular pattern, in which the tenascin staining outlined the border of the malignant tubules, and a diffuse pattern, characterized by diffuse interglandular stromal fibrillar distribution (Figure 1 A and B) . Either staining pattern was invariably seen throughout the interglandular stroma in each section. We did not see any correlation between tenascin expression and the number of microvessels in the tumour sections. No interobserver disagreement was seen.
Tenascin stainings and tumour stage, tumour differentiation and survival time Dukes ' stages C and D showed a tendency to have an increased proportion of diffuse tenascin staining. Compared with the reference category, Dukes' stage A, the increase was not significant (Pvalues 0.20 and 0.18), but a trend test yielded a result that was almost statistically significant (P = 0.06). There also appeared to be a connection between tumour differentiation and tenascin staining pattern, with a higher proportion of diffuse pattern among patients with moderately and poorly differentiated tumours (Pvalues 0.02 and 0.01 respectively; Table 1 ). The table also shows that the number of patients who died from cancer, or from other causes but with cancer, varied according to the Dukes' stage, tumour differentiation and tenascin staining pattern. those patients whose tumours showed a diffuse pattern than for those who showed a subglandular pattern. This was valid for both the entire group of patients (log-rank, P < 0.01, Figure 2A ) and the subset of patients with tumours in Dukes' stage A-C (log-rank, P < 0.03, Figure 2B ). Univariate survival analyses showed a significant relationship to survival for Dukes' stage, tumour differentiation and diffuse tenascin staining pattern (Table 2) . In a multivariate analysis encompassing all patients, Dukes' stage and age were independent prognostic factors for survival, whereas the diffuse tenascin staining pattern showed a borderline (P = 0.056) significant relationship to the survival time (Table 3) . The relative British Journal of Cancer (1997) 76(4), 526-530 hazard (RH) for patients with diffuse expression was 1.72 (95% confidence limits 0.98-2.99). Tumour differentiation lost its relationship to survival.
DISCUSSION
All specimens investigated exhibited strong tenascin staining of the interglandular tumour stroma, whereas they predominantly lacked tenascin staining in the adjacent normal bowel wall, thus indicating tenascin up-regulation in malignancy. This finding has been described by others in colorectal cancer (Sugawara et al, 1991; Riedel et al, 1992 Riedel et al, , 1995 Sakai et al, 1993; Hauptmann et al, 1995) and in several other tumour types (Natali and Zardi, 1989; Ibrahim et al, 1993; Moch et al, 1993; Shoji et al, 1993; Ikeda et al, 1995; Ilunga and Iriyama, 1995; Yoshida et al, 1995) . Like Sugawara et al (1991), we also found two different staining patterns. In contrast, Riedl et al (1992) did not discriminate various tenascin staining patterns but reported various degrees of extensive positivity in the basement membranes of colorectal carcinomas. Interestingly, Riedl et al (1995) reported that high serum levels of tenascin reflected metastatic disease. Consistent with the findings of Sugawara et al (1991) , we were able to demonstrate distribution differences between the two tenascin staining patterns according to Dukes' stage and tumour differentiation. In addition, we established a significantly shorter survival time for patients showing the diffuse tenascin staining pattern than for patients showing the subglandular tenascin staining pattern. A possible explanation for this difference in prognosis between the two staining patterns could be that subglandular tenascin may fulfil a protective function in preventing tumour invasion and/or metastases, as suggested previously (Sakakura and Kusakabe, 1994; Siri et al, 1995) .
It is recognized that until now the Dukes' classification has been the best known prognostic factor in colorectal cancer (Lindmark et al, 1994; Bosman, 1995) . However, there is also considerable variation in prognosis within the Dukes' stages (Newland et al, 1987; Lindmark et al, 1994) . Bentzen et al (1988) showed, for example, that some subgroups of Dukes' stage C patients had better prognosis than some subgroups of Dukes' stage B patients. For therapeutic and surveillance reasons, it is of importance to find stronger prognostic factors other than the original Dukes' classification, i.e. to be able to predict those patients with tumours in Dukes' stages B and C who are likely to have micrometastases requiring additional immediate treatment. Strong efforts have been made in the search for such markers that can replace or add information to that of the Dukes' stage. Jass et al (1987) have reported a prognostic scoring system that was found to be superior to that of the Dukes' stage for rectal cancer. The system considered the character of the invasive margin, peritumoral lymphocytic infiltration, local spread and number of metastatic lymph nodes. However, this scoring classification system has not been established, as yet, in clinical pathological practice, probably because the pathological examination is rather time-consuming. Several tumour markers also provide additional prognostic information, but their clinical relevance is yet to be defined as they mainly identify patients who already have metastases at diagnosis (Stahle et al, 1988; Lindmark et al, 1995) . We have recently observed that the number of microvessels in tumour sections contributes to the prognosis prediction in colorectal cancer . However, in the present study, we did not see any correlation between the tenascin expression and the number of microvessels in the tumour sections. Tumour cell DNA ploidy and cell proliferation, measured by flow cytometry, have not turned out to be strong prognostic factors beyond that of Dukes' stage in colorectal cancer (Lindmark et al, 1991; Bottger et al, 1993) . This also appears to be the case for p53 overexpression, although some studies have shown a correlation with prognosis (Mulder et al, 1995; Kressner et al, 1996) . Recent molecular studies suggest that the process of tumorigenesis in colorectal cancer proceeds through a series of genetic alterations (Fearon and Vogelstein, 1990) . Two reports have shown that allelic loss on chromosome 18q (DCC gene) is associated with poor prognosis in Dukes' stage B (O'Connel et al, 1992; Jen et al, 1994) . Further studies are needed, however, to clarify how genetic alterations can contribute to prognosis. As yet, no single studied prognostic marker has proved to be better for prediction than the Dukes' stage.
To summarize, the stromal fibrillar distribution of tenascin appears to be a potential prognostic marker. We were able to discriminate, on the basis of significant tenascin staining differences, between living patients with no evidence of disease and those who had died from cancer after a potentially curative resection for colorectal cancer. However, the strength of this finding was reduced after adjustment for the effects of Dukes' stage and age.
